A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines

Who May Qualify: - Male or female, aged ≥6 months (no upper limit unless one is required by local regulations) and bodyweight ≥5 kg - Ability to take oral medication - Fever defined as ≥38°C tympanic temperature or a history of fever within the last 24 hours - Acute uncomplicated P. falciparum monoinfection - Asexual P. falciparum parasitaemia: 1,000/µL to 250,000/µL determined on a peripheral blood film - Written willing to sign a consent form by the participant, or by the parent/guardian in case of children lower than the age of consent, and assent if required (per local regulations) - Willingness and ability of the participants or parents/guardians to comply with the study protocol for the duration of the study Who Should NOT Join This Trial: - Signs of severe malaria (adapted from WHO criteria) - Patients not fulfilling criteria for severe malaria but with other indication(s) for parenteral antimalarial treatment at the discretion of the treating physician - Haemoglobin \<7 g/dL at screening - Participants who have received artemisinin or a derivative within the previous 7 days OR lumefantrine or amodiaquine within the previous 14 days - In applicable countries: use of seasonal malaria chemoprophylaxis (SMC) within the last 30 days - Acute illness other than malaria requiring systemic treatment - Severe acute malnutrition - Known HIV, tuberculosis, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or other severe infection - For women of child-bearing age: pregnant, trying to get pregnant or lactating - History of allergy or known contraindication to any of the study drugs, including neuropsychiatric disorders and epilepsy - Previous splenectomy - Participation in the previous 3 months and/or ongoing follow-up for an interventional study (including FD-TACT) Always talk to your doctor about whether this trial is right for you.